Pharvaris (NASDAQ:PHVS) Director Sells $300,400.00 in Stock

September 12, 2026 by InsiderTrades.com

Key Points

Director Robert Glassman sold 8,000 Pharvaris shares at an average price of $37.55, generating approximately $300,400 and reducing his direct holdings by 43.24% to 10,500 shares.
Pharvaris reported positive Phase 3 results for once-daily extended-release deucrictibant, which reduced hereditary angioedema attack rates by 83% versus placebo. The company plans to begin regulatory submissions in the first half of 2027.
Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $59.50, although the clinical-stage company faces regulatory, competition, funding and execution risks.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Robert Glassman sold 8,000 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $37.55, for a total transaction of $300,400.00. Following the transaction, the director owned 10,500 shares in the company, valued at $394,275. The trade was a 43.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Pharvaris Trading Up 1.4%

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

NASDAQ:PHVS opened at $38.02 on Friday. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25. The firm has a fifty day simple moving average of $35.09 and a 200-day simple moving average of $31.38. The company has a market capitalization of $2.49 billion, a P/E ratio of -12.47 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently made changes to their positions in the company. venBio Partners LLC purchased a new position in Pharvaris in the second quarter valued at $160,569,809. Wellington Management Group LLP acquired a new position in shares of Pharvaris in the third quarter worth about $43,282,000. 5AM Venture Management LLC purchased a new stake in shares of Pharvaris during the 2nd quarter worth about $27,581,008. California State Teachers Retirement System grew its position in shares of Pharvaris by 3,210.1% during the 2nd quarter. California State Teachers Retirement System now owns 799,490 shares of the company's stock valued at $27,646,000 after acquiring an additional 775,337 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its position in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock valued at $45,796,000 after acquiring an additional 772,583 shares during the period.

Analyst Upgrades and Downgrades

PHVS has been the topic of several research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. Wells Fargo & Company raised their price objective on Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday. Royal Bank Of Canada upped their target price on Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, New Street Research set a $60.00 price target on shares of Pharvaris in a research report on Friday, August 14th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $59.50.

Check Out Our Latest Stock Report on PHVS

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.